Mark A. Kronenfeld

Mark A. Kronenfeld (board member) discloses dealings in Pacira BioSciences, Inc. to SEC (Form 4). In total, 21 filings cover trades dated from 11 September 2013 to 11 June 2025.

On the open market, the record shows 6 purchases worth €222k and 2 sales worth €552k. Sales outweigh purchases by €331k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 12 share grants and 1 option exercise.

In size, the median ticket on the buying side is €35k. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The record was last updated on 19 March 2026 with a share grant in Pacira BioSciences, Inc. The last insider purchase was made public on 8 March 2019, 2,787 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.